The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
Just days after revealing an agreement with Daiichi Sankyo over its Ranmark (denosumab) biosimilar, Fuji Pharma said on November 4 that it has also signed a contract with Johnson & Johnson’s Janssen Biotech covering its follow-on of the rheumatoid arthritis…
To read the full story
Related Article
- Fuji Inks Deal with Daiichi on Ranmark Biosimilar, Now Plans 2026 Launch
November 4, 2025
- Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut
September 22, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Shionogi’s Antibiotic Cefiderocol Approved in China
January 9, 2026
- Mochida’s EPA Drug Epadel S Wins Approval in China
January 9, 2026
- Keytruda Tops Japan Drug Sales Again in December, Marking 27-Month Run: Encise
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…